Thermo Fisher Scientific Completes Sale of Genevac

Apr 04, 2007

NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said it has completed the sale of its Genevac business to Riverlake Equity Partners.

Thermo said Genevac brought in around $17 million in annual sales.

As GenomeWeb News reported last October, the Federal Trade Commission and the European Commission required that Fisher Scientific divest the Ipswich, UK-based company before it can merge with Thermo Electron.

The FTC and the EC required Thermo to sell the business by April 9.

Breaking News

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.